A critical assessment of insulin sensitivity in women with and without breast cancer. Breast cancer continues to be a leading cause of death in women in the United States. It accounts for 18% of all female cancer deaths and approximately 46,000 women will die of breast cancer each year. Breast cancer risk has been associated with Western life-style, but it is difficult to identify what aspects of life impose this large risk for disease If these factors could be identified, preventative measures could be taken to reduce the risk level. The focus of this study is the exploration of a novel risk factor for breast cancer, namely insulin resistance and the presence of an excess amount of insulin in the blood (hyperinsulinemia). It has become clear that Western life-style is associated with an increase waist-to-hip ratio, also known as the apple shape, as opposed to the pear shape. Studies have shown that apple shaped women, despite normal glucose tolerance, are insulin resistant. The apple shape and obesity are recognized risks for the development of breast cancer and it seems likely that hyperinsulinemic insulin resistance represents the common feature responsible for this increased risk. Hyperinsulinemia associated with insulin resistance has been shown to effect multiple aspects of human sex steroid metabolism as well as rapid cellular growth. Thus, several mechanisms exist by which hyperinsulinemic insulin resistance could promote the development of breast cancer. The above observations suggest that hyperinsulinemic insulin resistance may represent both an early marker for disease predisposition as well as a reversible risk factor for breast cancer. Subjects from the Massey Cancer Center at MCV and from the mammography center at MCV will be invited to participate in the study. Medical histories will be taken, and social histories (smoking, exercise, alcohol intake) will be evaluated. Women with known diabetes mellitis will be excluded. There will be two groups, one of women with breast cancer and the other of women without breast cancer. 200 women in the study will come to the General Clinical Research Center after an overnight fast. Height, weight, waist-to-hip ratio, and percent body fat will be recorded. Fasting blood samples will be drawn for determination of basal serum insulin, glucose, estrogen, androgen, and sex hormone binding globulin levels. An insulin tolerance test will be given to assess insulin sensitivity. Four groups of variables will be identified: insulin sensitivity, biochemical factors, heredity factors, and lifestyle factors. Analysis of these groups will help identify risk factors.

Project Start
1999-12-01
Project End
2000-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
38
Fiscal Year
2000
Total Cost
$648
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Holkova, Beata; Yazbeck, Victor; Kmieciak, Maciej et al. (2017) A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma 58:1349-1357
Corey, Kathleen E; Vuppalanchi, Raj; Vos, Miriam et al. (2015) Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 60:360-7
Eaton, J E; Juran, B D; Atkinson, E J et al. (2015) A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther 41:980-90
Worthington Jr, Everett L; Berry, Jack W; Hook, Joshua N et al. (2015) Forgiveness-reconciliation and communication-conflict-resolution interventions versus retested controls in early married couples. J Couns Psychol 62:14-27
Holkova, Beata; Kmieciak, Maciej; Perkins, E Brent et al. (2014) Phase I trial of bortezomib (PS-341; NSC 681239) and ""nonhybrid"" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20:5652-62
Noureddin, Mazen; Yates, Katherine P; Vaughn, Ivana A et al. (2013) Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 58:1644-54
Lo, D J; Anderson, D J; Weaver, T A et al. (2013) Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant 13:320-8
Poklepovic, Andrew; Youssefian, Leena E; Youseffian, Leena et al. (2013) Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Invest New Drugs 31:937-42
Holkova, Beata; Supko, Jeffrey G; Ames, Matthew M et al. (2013) A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res 19:1873-83
Lo, D J; Farris, A B; Song, M et al. (2013) Inhibition of ?v?6 promotes acute renal allograft rejection in nonhuman primates. Am J Transplant 13:3085-93

Showing the most recent 10 out of 367 publications